Analysts Issue Forecasts for STERIS’s Q3 Earnings (NYSE:STE)

STERIS plc (NYSE:STE) – Stock analysts at Zacks Research lifted their Q3 2025 earnings estimates for shares of STERIS in a research note issued to investors on Tuesday, January 21st. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $2.31 per share for the quarter, up from their previous estimate of $2.30. The consensus estimate for STERIS’s current full-year earnings is $9.10 per share. Zacks Research also issued estimates for STERIS’s FY2025 earnings at $9.08 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.37 EPS, Q3 2026 earnings at $2.54 EPS, Q4 2026 earnings at $2.81 EPS, FY2026 earnings at $9.99 EPS, Q1 2027 earnings at $2.48 EPS, Q2 2027 earnings at $2.59 EPS, Q3 2027 earnings at $2.63 EPS and FY2027 earnings at $10.35 EPS.

Several other analysts have also recently commented on STE. Stephens reiterated an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research note on Thursday, November 7th. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Friday, November 8th. StockNews.com downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. Finally, JMP Securities reissued a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a report on Monday, November 18th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, STERIS has an average rating of “Moderate Buy” and a consensus price target of $262.50.

STERIS Price Performance

Shares of NYSE STE opened at $217.25 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. STERIS has a one year low of $197.82 and a one year high of $248.24. The firm has a market capitalization of $21.44 billion, a P/E ratio of 49.60 and a beta of 0.84. The company’s fifty day moving average is $211.60 and its two-hundred day moving average is $224.70.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The business had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same period in the prior year, the business posted $2.03 EPS. The company’s revenue for the quarter was up 7.3% on a year-over-year basis.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th were issued a $0.57 dividend. The ex-dividend date of this dividend was Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.05%. STERIS’s dividend payout ratio (DPR) is 52.05%.

Insider Activity

In other news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the transaction, the senior vice president now owns 11,372 shares of the company’s stock, valued at $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Franklin Resources Inc. lifted its position in STERIS by 171.2% during the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock worth $191,370,000 after buying an additional 529,308 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of STERIS by 7,418.7% in the third quarter. Assenagon Asset Management S.A. now owns 309,771 shares of the medical equipment provider’s stock worth $75,132,000 after acquiring an additional 305,651 shares during the last quarter. Swedbank AB acquired a new stake in shares of STERIS in the third quarter worth approximately $28,251,000. Benjamin Edwards Inc. grew its stake in shares of STERIS by 2,123.2% during the 3rd quarter. Benjamin Edwards Inc. now owns 113,672 shares of the medical equipment provider’s stock valued at $27,574,000 after buying an additional 108,559 shares during the period. Finally, Principal Financial Group Inc. grew its position in STERIS by 9.5% during the third quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider’s stock valued at $270,230,000 after acquiring an additional 96,336 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.